SOPH vs. VTYX, CADL, JSPR, IVVD, ADAP, BDTX, CRBU, MGTX, PSTX, and STRO
Should you be buying SOPHiA GENETICS stock or one of its competitors? The main competitors of SOPHiA GENETICS include Ventyx Biosciences (VTYX), Candel Therapeutics (CADL), Jasper Therapeutics (JSPR), Invivyd (IVVD), Adaptimmune Therapeutics (ADAP), Black Diamond Therapeutics (BDTX), Caribou Biosciences (CRBU), MeiraGTx (MGTX), Poseida Therapeutics (PSTX), and Sutro Biopharma (STRO). These companies are all part of the "medical" sector.
Ventyx Biosciences (NASDAQ:VTYX) and SOPHiA GENETICS (NASDAQ:SOPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, community ranking, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.
In the previous week, Ventyx Biosciences had 2 more articles in the media than SOPHiA GENETICS. MarketBeat recorded 6 mentions for Ventyx Biosciences and 4 mentions for SOPHiA GENETICS. Ventyx Biosciences' average media sentiment score of 0.49 beat SOPHiA GENETICS's score of 0.28 indicating that SOPHiA GENETICS is being referred to more favorably in the news media.
Ventyx Biosciences has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500.
Ventyx Biosciences presently has a consensus price target of $21.75, suggesting a potential upside of 336.75%. SOPHiA GENETICS has a consensus price target of $8.00, suggesting a potential upside of 75.05%. Given SOPHiA GENETICS's higher possible upside, research analysts clearly believe Ventyx Biosciences is more favorable than SOPHiA GENETICS.
Ventyx Biosciences received 11 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 72.73% of users gave SOPHiA GENETICS an outperform vote while only 49.09% of users gave Ventyx Biosciences an outperform vote.
SOPHiA GENETICS has higher revenue and earnings than Ventyx Biosciences. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Ventyx Biosciences, indicating that it is currently the more affordable of the two stocks.
97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 31.6% of SOPHiA GENETICS shares are held by institutional investors. 24.4% of Ventyx Biosciences shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Ventyx Biosciences has a net margin of 0.00% compared to Ventyx Biosciences' net margin of -113.71%. Ventyx Biosciences' return on equity of -47.56% beat SOPHiA GENETICS's return on equity.
Summary
SOPHiA GENETICS beats Ventyx Biosciences on 9 of the 17 factors compared between the two stocks.
Get SOPHiA GENETICS News Delivered to You Automatically
Sign up to receive the latest news and ratings for SOPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SOPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SOPHiA GENETICS Competitors List
Related Companies and Tools
